2024 International Congress Archives - Page 10 of 181

Laboratory changes of the liver function in the patients with Wilson’s disease

I. Voloshyn-Haponov, A. Teslenko, L. Cherkashyna, O. Korzh (Kharkiv, Ukraine)
Lance – Adams Syndrome: a Case Series from Vietnam

HA. Nguyen, HK. Vo (Hanoi, Viet Nam)
Late-onset neurologic Wilson’s disease: case series

I. Minaev, E. Nuzhnyi, V. Poleschuk, A. Protopopova, N. Abramycheva, S. Illarioshkin (Moscow, Russian Federation)
Latent Genetic Architecture of Parkinson’s Disease Risk factors and Comorbidities

J. Kim, I. Foote, S. Bandres-Ciga, 23. Research Team, C. Marshall, A. Grotzinger3, A. Singleton, A. Brentnall, C. Blauwendraat, A. Noyce, G. Genetics Program (London, United Kingdom)
Leg Stereotypy Syndrome: Phenomenological and Quantitative Analysis

A. Yilmaz, E. Ruzicka, J. Jankovic (Houston, USA)
Legmain/Asparaginyl endopeptidase-resistant tau fibril fold produces corticobasal degeneration-specific C-terminal tau fragment

D. Taniguchi, T. Hatano, Y. Imai, N. Hattori (Tokyo, Japan)
Lessons from the COVID-19 Lockdown: A Novel Mentorship Program for Young Neurosurgeons, Neurologists and Medical Students

M. Elsayed, A. Motawei, A. Abdelrahman, A. Elgohary, B. Lashin, F. Monib, A. Abdelaal, E. Abdelazim, H. Basem (Mansoura, Egypt)
Levels of change in interleukin-6 levels according to clinical forms of Parkinson’s disease in patients with and without Covid-19

B. Muminov, R. Matmurodov (Tashkent, Uzbekistan)
Levels of change in interleukin-6 levels according to clinical stages of Parkinson’s disease in patients with and without Covid-19

R. Juraev, B. Muminov, R. Matmurodov (Tashkent, Uzbekistan)
Levels of ferritinemia in Parkinson’s disease patients who underwent Covid-19

B. Amonov, R. Matmurodov, B. Muminov (Tashkent, Uzbekistan)
Leveraging Large-Scale Proteomics to Identify Protein Quantitative Trait Loci and Causal Effects on Parkinson’s Disease

M. Lai, B. Benitez (Boston, USA)
Levodopa response is an inadequate and often biased correlate of STN-DBS outcomes

J. Younce, S. Norris, J. Perlmutter (Chapel Hill, USA)
Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience

J. Szász, V. Constantin, K. Orbán-Kis, S. Bataga, R. Neagoe, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmári (Targu Mures, Romania)
Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study

AA. Vanderplas (Leiderdorp, Netherlands)
Lifestyle Medicine for Cervical Dystonia: a New View on Treatment

L. Centen, M. van Egmond, M. Tijssen (Groningen, Netherlands)
Linear Mixed-Effect Modelling of Antisaccades in Parkinson’s Disease and Progressive Supranuclear Palsy

S. Patel, O. Patel, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)
Lingual-Masticatory Myorhythmia and Palatal Tremor as a Presentation of Anti-IgLON5 Disease

RY. Wu, CC. Hsieh, YT. Sun, TL. Lee (Tainan, Taiwan)
Listening to the Insight: The Underdiagnosis of Depression in People Living with Parkinson’s Disease

G. Rivera-Monroy, RJ. Baños-Betancourt, K. Velázquez-Román, CF. álvarez-Hernández, AL. Guerra-Anzaldo, WF. Moguel-Cardín, A. Domínguez-García, MF. Medina-Pérez, JC. Delgado-Uriarte, NP. Moreno-Aldama, A. Uribe-León, MC. Unda-Mcfarlane, AJ. Hernández-Medrano, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)
Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.

T. Guttuso, JR., R. Shepherd (Williamsville, USA)
Loganic Acid Alleviates the Bidirectional Olfactory-Brain NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental Models of Parkinson’s Disease

S. Panda, P. Panja, V. Naidu (Guwahati, India)
Loneliness Relates to Gait Over Other Features of Parkinsonism

D. Gonzalez, R. Wilson, M. Tosin, C. Goetz (Chicago, USA)
Long term evaluation of gluten-free diet in Parkinson´s disease patients

H. Brožová, K. Poláková, T. Gentileová, M. Fialová, M. Kubjatková, J. Rusz, M. Sap, M. Kuzma, H. Pelantová, M. Jandová, D. Funda (Prague, Czech Republic)
Long-read sequencing to identify unrevealed second hit in autosomal recessive Parkinson’s disease

K. Daida, H. Yoshino, K. Billingsley, L. Malik, B. Baker, R. Genner, K. Paquette, M. Ishiguro, M. Funayama, Y. Li, K. Nishioka, C. Blauwendraat, N. Hattori (Bethesda, USA)
Long-term Blood Pressure Measures in Incident Parkinson’s Disease in the Framingham Heart Study.

S. O'Shea, Y. Liu, Y. Li, A. Gurnani, J. Dookhy, S. Frank, R. Au, J. Mez, T. Ang, L. Shih (New York, USA)
Long-term effects of Deep Brain Stimulation on gait and postural control in Parkinson’s disease

S. Zheng, JL. Wu, SQ. Liang, Y. Yu, JC. Wu, HT. Li, YY. Cheng (tianjin, China)
Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson’s Disease

A. Espay, R. Pahwa, A. Ellenbogen, F. Stocchi, N. Giladi, L. Salin, N. Sasson, J. Pereira, O. Rascol (Cincinnati, USA)
Long-term evaluation of advanced Parkinson’s disease burden and clinical outcomes: results from the PROSPECT observational study

A. Espay, H. Watanabe, A. Lehn, F. Ory-Magne, T. Mestre, D. Safarpour, L. Bergmann, P. Kukreja, K. Onuk, P. Alonso (Cincinnati, USA)
Long-Term Evolution of Advanced Parkinson’s Disease Burden: Subgroup Analysis from the 24 Month International PROSPECT Observational Study

O. de Fabregues, D. Falconer, S. Heshmat, D. Houghton, D. Maltete, Y. Mukai, M. Rollins, L. Bergmann, P. Kukreja, K. Onuk, J. Sarna (Barcelona, Spain)
Long-term follow up of unilateral deep brain stimulation for Parkinson’s disease

F. Sarmento, A. Daga, A. Wang, T. de Araujo, S. Aghili-Mehrizi, J. K. Wong (Gainesville, USA)
Long-term Physical Exercise on Bone Mineral Density, Balance and Gait in Older Adults with Mild to Moderate Parkinson’s Disease

L. Leandro, T. Zotz, O. Matos, M. Olandoski, C. Moreira (Pinhais, Brazil)
Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension

F. Bergquist, J. Aldred, C. Carroll, E. Danielsen, M. Facheris, R. Gupta, A. Jeong, A. Spiegel, V. Fung (Mölndal, Sweden)
Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up

R. Hauser, V. Fung, T. Kimber, K. Klos, M. Facheris, A. Jeong, J. Jia, A. Spiegel, M. Soileau (Tampa, USA)
Long-term Safety of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

R. Freeman, I. Biaggioni, R. Vickery, L. Norcliffe-Kaufmann, T. Guerin, M. Bryarly, V. Iodice, M. Rudzniska-Bar, M. Boczarska-Jedynak, C. Oehlwein, C. Shibao, H. Kaufmann (Boston, USA)
Longevity of Motor Benefit Achieved with Deep Brain Stimulation (DBS) of the Subthalamic Nucleus (STN) in a Single Center Cohort at the Decade Mark Post-Implantation.

D. Caputo, R. Dipaola, S. Danish, E. Hargreaves (Neptune, USA)
Longitudinal Analysis of fragile X-associated tremor/ataxia syndrome Progression: A One-Year Follow-Up of 24 Patients

M. Tosin, D. Hall, L. Quinchia (Chicago, USA)
Longitudinal Assessment of Dystonic Symptoms in Rapid-Onset Dystonia-Parkinsonism: genetic dystonia symptoms vary over time

I. Haq, V. Wheelock, L. Ozelius, B. Snively, E. Napoli, K. Sweadner, A. Brashear (Miami, USA)
Longitudinal change in brain function and structure related to plasma neurofilament light protein in early-stage Parkinson’s disease

Y. Xiao, SC. Wang, YB. Hou, HF. Shang (Chengdu, China)
Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease

T. Yamamoto, Y. Yamanaka, S. Hirano, A. Sugiyama, N. Araki, Y. Higuchi, S. Kuwabara (Chiba, Japan)
Longitudinal Gait Speed Analysis at Prodromal and Early Stage of Parkinson’s Disease

S. Sambin, M. Houot, F. Khoury, G. Mangone, L-L. Mariani, I. Arnulf, S. Lehericy, M. Vidailhet, J-C. Corvol (Paris, France)
Longitudinal patterns of Anxiety and Depression in patients with Parkinson’s Disease

O. Lawal, M. Morales, S. Shakya, J. Savitt, S. Reich, A. Gruber-Baldini, L. Shulman, R. von Coelln (Baltimore, USA)
Longitudinal progress and clinical relevance of 18F-Florzolutau PET in patients with PSP: a one-year follow-up study

J. Wang, F. Liu, C. Zuo (Shanghai, China)
Longitudinal Relationship Between Brain Metabolism and Clinical Changes in Huntington’s Disease

A. Gravier, S. Lavisse, R. Massart, A. Gil-Salcedo, P. Lemercier, O. Barret, V. Gaura, AC. Bachoud-Levi, P. Remy (Créteil, France)
Longitudinal Structural and Functional Correlates of Progression in Isolated Rapid Eye Movement Sleep Behaviour Disorder

L. Churchill, YC. Chen, J. Anderson, A. Ignatavicius, SJG. Lewis, E. Elie (Camperdown, Australia)
Longitudinal Studies of LFP Activities During Acute and Chronic DBS Stimulation in PD Patients

Y. Zhao, V. Rayudu, S. Santacruz, M. Varga (Austin, USA)
Looking Away: Anxiety Interferes with the Ability of Freezers to Attend to Visual Cues

P. Norouzian, A. Zafar, S. Lewis, K. Ehgoetz Martens (Waterloo, Canada)
Low intensity focused pulsed ultrasound as a treatment of essential tremor: a case series

P. Medeiros Lacerda, G. Nunes, M. Torres, R. Iglesio, K. Massruha, M. Silva, V. Maciel, E. Barbosa, M. Teixeira, R. Nogueira, R. Cury (São Paulo, Brazil)
Lower Incidence of Parkinson’s Disease in Patients with Metabolic Syndrome or any of its Components: A Longitudinal Study

R. Djaldetti, H. Avisar, U. Greenbaum, B. Lerner (Petah Tiqva, Israel)
Lower plasma piperine levels in Parkinson’s disease: a PPMI metabolomics analysis

N. Xia, J. Ripping, R. Bakshi, E. Macklin, S. Molsberry, X. Chen, A. Ascherio, M. Schwarzschild (Charlestown, USA)
LRRK2 and GBA Founder Mutations and their Interactions in Parkinson’s Disease

M. Kmiecik, G. Riboldi, R. Schneider, K. Stagaman, T. Filshtein Sonmez, A. Guan, M. Wetzel, P. Fontanillas, M. Holmes, S. Aslibekyan, L. Norcliffe-Kaufmann (Sunnyvale, USA)
LRRK2 G2019S mutant damages mitochondrial transfer by a Drp1-STX17 depend pathway in Parkinson’s disease

X. Cheng (Suzhou, China)
LRRK2 Gene Mutation in Parkinson’s Disease

A. Abbes, M. Mhiri, R. Ben Dhia, N. Gouta, M. Frih Ayed (Monastir, Tunisia)
LRRK2 I1371V Mutation: Unraveling Pathogenic Mechanisms in Dopaminergic Neurons via Membrane Fluidity & Calcium Dysregulation using PD Patient iPSCs

I. Datta, S. Jagtap, V. Holla, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)
LRRK2 in Parkinson’s Disease: A per-domain rare-variant burden study

S. Parlar, K. Senkevich, E. Yu, J. Ruskey, J. Ahmad, F. Asayesh, D. Spiegelman, C. Waters, O. Monchi, Y. Dauvilliers, N. Dupré, L. Greenbaum, S. Hassin-Baer, I. Miliukhina, A. Timofeeva, A. Emelyanov, S. Pchelina, R. Alcalay, E. Fon, Z. Gan-Or (Montreal, Canada)
LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics

D. Jennings, S. Huntwork-Rodriguez, J. Kluss, S. Ota, S. Dhuria, R. Maciuca, K. Fraser, B. Hersh, Z. Berger, C. Ho, P. Chin (South San Francisco, USA)
LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization

L. Chahine, D. Lafontant, C. Choi, H. Iwaki, M. Brumm, R. Alcalay, K. Nudelman, A. Dagher, K. Merchant, A. Vo, Q. Tao, C. Venuto, K. Kieburtz, K. Poston, S. Bressman, P. Gonzalez Latapi, B. Avants, C. Coffey, D. Jennings, E. Tolosa, A. Siderowf, K. Marek, T. Simuni (Pittsburgh, USA)
Lumbar Punctures in Parkinson’s Research

A. Navangul, H. Matthews, M. Bartlett, H. Groves, S. Stott, A. Noyce (London, United Kingdom)
Lyme disease presenting as a rapidly progressive MSA-C look alike

L. Zünd-Hofer, F. Brugger (Sankt Gallen, Switzerland)
Lysosomal network defects in parkinsonian patients carrying rare variants in lysosomal hydrolytic enzyme genes

J. Hoenicka, A. Pascual, O. de Fàbregues, M. Frias, L. Vela, M. de Lucca, P. García-Ruiz, C. Feliz, M. Marchen, R. Repossi, G. Fernández, M. Roldán, F. Palau (Esplugues de Llobregat, Spain)